Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Oppenheimer

Equities research analysts at Oppenheimer started coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set an “outperform” rating and a $52.00 price target on the stock. Oppenheimer’s target price indicates a potential upside of 99.08% from the company’s previous close. Oppenheimer also issued estimates for Apellis Pharmaceuticals’ Q2 2019 earnings at ($0.80) EPS, Q3 2019 earnings at ($0.84) EPS, Q4 2019 earnings at ($0.84) EPS, FY2019 earnings at ($3.34) EPS, Q1 2020 earnings at ($0.82) EPS, Q2 2020 earnings at ($0.82) EPS, Q3 2020 earnings at ($0.84) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.30) EPS, FY2021 earnings at ($3.01) EPS, FY2022 earnings at ($0.94) EPS and FY2023 earnings at $9.19 EPS.

Several other analysts also recently commented on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $107.00 price objective on shares of Perrigo in a research report on Wednesday, May 8th. Robert W. Baird began coverage on shares of Uniqure in a research report on Thursday, March 28th. They set an “outperform” rating and a $85.00 price objective on the stock. ValuEngine raised shares of Vistra Energy from a “hold” rating to a “buy” rating in a research report on Wednesday, July 3rd. Zacks Investment Research raised shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Finally, Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Sunday, June 16th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $43.29.

Shares of NASDAQ:APLS traded down $0.76 during midday trading on Tuesday, reaching $26.12. The company’s stock had a trading volume of 245,800 shares, compared to its average volume of 429,427. The business has a 50 day moving average of $22.58. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -11.16 and a beta of 0.74. The company has a quick ratio of 15.23, a current ratio of 15.23 and a debt-to-equity ratio of 0.05. Apellis Pharmaceuticals has a 12-month low of $11.45 and a 12-month high of $27.41.



Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.20). As a group, analysts predict that Apellis Pharmaceuticals will post -3.16 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in APLS. Hillhouse Capital Advisors Ltd. purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $29,410,000. BlackRock Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 30.8% during the 4th quarter. BlackRock Inc. now owns 3,730,626 shares of the company’s stock valued at $49,208,000 after acquiring an additional 877,431 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $4,313,000. Assenagon Asset Management S.A. purchased a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at about $6,025,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 21.7% during the 1st quarter. Victory Capital Management Inc. now owns 1,688,663 shares of the company’s stock valued at $32,929,000 after acquiring an additional 300,900 shares during the last quarter. 63.45% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Further Reading: Purposes and Functions of the Federal Reserve

The Fly

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.